Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Recurrence × tafasitamab × Clear all

Phase

Status

Withdrawn 1 Terminated 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 5 Lymphoma, B-Cell 3 Lymphoma 3 Lymphoma, Mantle-Cell 2 Recurrence 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Burkitt Lymphoma 1

Interventions

venetoclax 19 Cyclophosphamide 17 pembrolizumab 15 Dexamethasone 14 Cytarabine 12 fludarabine 11 Azacitidine 10 Gemcitabine 9 pomalidomide 7 Rituximab 7 Carboplatin 7 selinexor 6 glofitamab 6 Temozolomide 6 Lenalidomide 6 Granulocyte Colony-Stimulating Factor 6 fludarabine phosphate 5 Paclitaxel 5 Oxaliplatin 5 Injections 5 Cisplatin 5 zanubrutinib 4 ruxolitinib 4 obinutuzumab 4 daratumumab 4 carfilzomib 4 Surgical Procedures, Operative 4 Nivolumab 4 Decitabine 4 Cladribine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07126236 2025-08-17

REPIFIR

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2 Recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡